Bipolar disorder treatment for Jupiter — the diagnosis primary care misses.
A specialist outpatient program for clients in Jupiter. PHP, IOP, in-house psychiatry, sober-living network, family programming. Same admissions team, 24/7.
Start the conversation Or call directly — (561) 421-4107Local options exist. This is the clinical specialist.
For adults in Jupiter, Abacoa, and Tequesta, RECO Integrated Psychiatry's Delray Beach office is a 45-minute drive south on I-95 — close enough for maintenance visits, far enough for genuine clinical separation from local triggers. The practice runs the medications that require the most careful monitoring: lithium with quarterly levels and TSH, lamotrigine with slow titration for Stevens-Johnson risk, valproate with LFTs and platelet tracking. Diagnostic clarification using the MDQ, HCL-32, mood charting, and structured collateral history is the load-bearing piece of bipolar care, and it is not rushed into a 15-minute slot.
Jupiter sits 32 miles north of RECO Integrated Psychiatry’s Delray Beach office — about 45 minutes down I-95 outside of rush hour. For adults living in Abacoa, Jupiter Inlet Colony, or Tequesta, that distance is workable for regular medication management and quarterly lab draws, and far enough from local routines that the Delray office functions as genuine clinical space. Bipolar disorder is one of the diagnoses where unhurried evaluation and consistent monitoring change outcomes more than any single prescribing decision.
Bipolar I versus bipolar II versus bipolar spectrum
The DSM-5 distinction between bipolar I, bipolar II, and the bipolar spectrum drives every subsequent pharmacologic decision. Bipolar I requires at least one manic episode — seven or more days of elevated or irritable mood with functional impairment or hospitalization, or any duration if psychotic features are present. Bipolar II requires a hypomanic episode of at least four days plus a history of major depressive episodes, and by definition excludes full mania. The bipolar spectrum — other specified bipolar and related disorder, cyclothymia, subthreshold bipolar, antidepressant-induced hypomania — captures presentations with clear cyclicity that don’t meet full threshold criteria.
The distinction is not academic. Bipolar I responds well to lithium plus a second-generation antipsychotic across manic, depressive, and maintenance phases. Bipolar II depression responds robustly to lamotrigine and quetiapine but shows less consistent response to lithium monotherapy and higher rates of antidepressant-induced switching. Bipolar spectrum presentations require the most careful pharmacology — antidepressants are used cautiously, if at all, and only with mood stabilizer cover.
Diagnostic clarification at RECO uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist (HCL-32), longitudinal mood charting, and structured collateral history from family members when the client consents. Misdiagnosis of bipolar depression as unipolar depression is the single most common driver of treatment failure in this population — an SSRI given without a mood stabilizer can trigger switching, rapid cycling, or a mixed state.
Lithium — the treatment we take seriously when others don’t
Lithium remains the most effective long-term mood stabilizer for bipolar I disorder and the only psychotropic with strong evidence for reducing completed suicide. It works across phases — acute mania, bipolar depression with more modest effect, and maintenance — with efficacy that no newer agent has matched in head-to-head trials for classic euphoric mania.
Initiation requires baseline TSH, creatinine and eGFR, serum calcium, CBC, and a pregnancy test where relevant. Maintenance target serum level is 0.6-1.0 mEq/L drawn twelve hours post-dose; acute mania often requires 0.8-1.2 mEq/L. Levels are checked five to seven days after each dose change, then quarterly for the first year and every six months once stable, with TSH and creatinine at the same intervals. Weight, blood pressure, and metabolic parameters are tracked longitudinally.
Many prescribers avoid lithium because the monitoring cadence is inconvenient and the therapeutic window is narrow. RECO’s protocol builds monitoring into the treatment plan, coordinates lab draws with LabCorp and Quest locations convenient to Jupiter, and manages the tolerability issues — tremor, polyuria, thyroid effects, weight — as they arise. For clients who tolerate lithium, the long-term outcomes justify the workload.
Second-generation antipsychotics and where they fit
Second-generation antipsychotics carry FDA indications across specific phases of bipolar illness, and phase-matched selection is the standard of care. Quetiapine is indicated for acute mania, bipolar depression, and maintenance, and remains one of the most-used agents for bipolar depression outside of lamotrigine. Lurasidone is indicated for bipolar I depression with a favorable metabolic profile. Aripiprazole and cariprazine are indicated for acute mania and maintenance; cariprazine additionally has evidence in bipolar depression. Olanzapine and the olanzapine-fluoxetine combination cover mania and bipolar depression respectively, with weight and metabolic burden that limits long-term use. Risperidone is effective in mania.
Monitoring follows APA guidelines: weight and BMI at baseline and quarterly, fasting glucose or HbA1c and a lipid panel at baseline, three months, and annually, and blood pressure at each visit. Prolactin is checked when clinically indicated. Selection is driven by phase of illness, tolerability profile, prior response history, and the client’s tolerance for specific side effects — a client who cannot accept weight gain will not stay on olanzapine, and prescribing adjusts accordingly.
Lamotrigine, valproate, and the anticonvulsant options
Lamotrigine has the strongest evidence for bipolar II depression and for maintenance where depression is the predominant pole. It is not effective for acute mania. Titration is deliberately slow — 25 mg daily for two weeks, 50 mg for two weeks, 100 mg for one week, then 200 mg — because of the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, which cluster in the first eight weeks. Any rash during titration triggers immediate discontinuation and dermatologic evaluation.
Valproate (divalproex) is effective for acute mania, mixed states, and rapid cycling. Serum level target is 50-125 mcg/mL, with baseline and periodic LFTs, CBC with platelets, and ammonia if clinically indicated. Weight, alopecia, and PCOS-spectrum effects in women of reproductive age are tracked. Valproate is contraindicated in pregnancy given established teratogenicity.
Carbamazepine is a second-line mood stabilizer used when first-line agents fail or are not tolerated. It requires HLA-B*1502 screening in patients of Asian ancestry, monitoring for hyponatremia and blood dyscrasias, and awareness of significant CYP450 induction that affects concurrent medications including oral contraceptives. RECO’s bipolar disorder treatment program runs each of these protocols with the labs and follow-up cadence they require.
What to expect on the first visit
The initial psychiatric evaluation runs 60 to 90 minutes. It covers a longitudinal mood history, structured screening with the MDQ, HCL-32, PHQ-9, and GAD-7, adult ADHD screening with the ASRS where indicated, sleep and circadian history, substance use screening, family psychiatric history, prior medication trials with response and tolerability, and current medications and medical comorbidities. Collateral from a spouse, parent, or adult child is invited when the client consents — bipolar diagnosis often depends on someone else’s recollection of hypomanic episodes the client did not recognize as pathological at the time.
Baseline labs are ordered before or during the first visit depending on the medications under consideration. A treatment plan is discussed rather than dictated — mood stabilizer choice, monitoring schedule, and coordination with psychotherapy modalities that have evidence in bipolar disorder (interpersonal and social rhythm therapy, family-focused therapy, CBT for bipolar) are decided together.
Insurance and admissions from Jupiter
RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Coverage is verified before the first visit and the expected copay or coinsurance is confirmed in writing so there are no billing surprises. Out-of-network reimbursement via superbill is available for plans that are not directly contracted.
Telepsychiatry is offered for follow-up medication management when clinically appropriate, which reduces the drive burden from Jupiter, Tequesta, and Admirals Cove between in-person visits. Acute mania, initial evaluation, and any lab-heavy stabilization phase are handled in person at the Delray Beach office.
Serving residents of: Abacoa, Jupiter Inlet Colony, Tequesta, Admirals Cove, Jonathan's Landing.
If it's any of these, we can help.
From Jupiter callers, most asked.
Does insurance cover bipolar disorder treatment at RECO from Jupiter?
How long does bipolar disorder treatment take?
What happens at the first psychiatric evaluation?
How do you tell bipolar depression apart from major depressive disorder?
How do I get to RECO Integrated Psychiatry from Jupiter?
Can family members be involved in bipolar treatment?
Other jupiter-area communities we serve.
Confidential. No commitment.
Tell us a little and a real human from admissions will call you back. We verify insurance benefits within minutes and tell you honestly whether RECO Integrated Psychiatry is the right fit — including if we should refer you elsewhere.